Literature DB >> 9208842

Functionally distinct isoforms of STAT5 are generated by protein processing.

M Azam1, C Lee, I Strehlow, C Schindler.   

Abstract

The interleukin-3 family of cytokines, which play an important role in the development of myeloid lineages, transduce signals through the JAK-STAT pathway. Previous studies demonstrate that this process entails the activation of four distinct isoforms of STAT5, where two shorter isoforms are activated in a distinct population of cells. We now demonstrate that the shorter isoforms represent carboxy-terminal truncations. Moreover, these truncations are not generated by RNA processing, but by a specific proteolytic activity. Consistent with the notion that truncated STAT5 isoforms transduce distinct signals, they fail to promote the activation of several known interleukin-3 target genes. These studies suggest that the activity of a specific protease may play a critical role in defining the biological responses transduced by STAT5.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9208842     DOI: 10.1016/s1074-7613(00)80445-8

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  26 in total

1.  Functional interaction of STAT5 and nuclear receptor co-repressor SMRT: implications in negative regulation of STAT5-dependent transcription.

Authors:  H Nakajima; P K Brindle; M Handa; J N Ihle
Journal:  EMBO J       Date:  2001-12-03       Impact factor: 11.598

Review 2.  Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas.

Authors:  Tracey J Mitchell; Susan John
Journal:  Immunology       Date:  2005-03       Impact factor: 7.397

Review 3.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 4.  Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency.

Authors:  J J O'Shea; L D Notarangelo; J A Johnston; F Candotti
Journal:  J Clin Immunol       Date:  1997-11       Impact factor: 8.317

5.  Signal transduction activator of transcription 5 (STAT5) dysfunction in autoimmune monocytes and macrophages.

Authors:  S A Litherland; T X Xie; K M Grebe; A Davoodi-Semiromi; J Elf; N S Belkin; L L Moldawer; M J Clare-Salzler
Journal:  J Autoimmun       Date:  2005-03-23       Impact factor: 7.094

6.  Rapid inhibition of interleukin-6 signaling and Stat3 activation mediated by mitogen-activated protein kinases.

Authors:  T K Sengupta; E S Talbot; P A Scherle; L B Ivashkiv
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

7.  Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.

Authors:  J Schwaller; J Frantsve; J Aster; I R Williams; M H Tomasson; T S Ross; P Peeters; L Van Rompaey; R A Van Etten; R Ilaria; P Marynen; D G Gilliland
Journal:  EMBO J       Date:  1998-09-15       Impact factor: 11.598

Review 8.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

Review 9.  Role of STAT3 in Genesis and Progression of Human Malignant Gliomas.

Authors:  Zangbéwendé Guy Ouédraogo; Julian Biau; Jean-Louis Kemeny; Laurent Morel; Pierre Verrelle; Emmanuel Chautard
Journal:  Mol Neurobiol       Date:  2016-09-22       Impact factor: 5.590

10.  A sequence of the CIS gene promoter interacts preferentially with two associated STAT5A dimers: a distinct biochemical difference between STAT5A and STAT5B.

Authors:  F Verdier; R Rabionet; F Gouilleux; C Beisenherz-Huss; P Varlet; O Muller; P Mayeux; C Lacombe; S Gisselbrecht; S Chretien
Journal:  Mol Cell Biol       Date:  1998-10       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.